Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than ...

Amgen (NasdaqGS:AMGN) announced a new collaboration with the National Organization for Rare Disorders to speed rare ...

Operator: My name is Julianne, and I will be your conference facilitator today for the Amgen Q3 2026 Earnings Conference Call ...

By Deena Beasley Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug ...

With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 ...

Amgen's Imdelltra has shown that it can significantly reduce the risk of death in patients who have extensive-stage small ...

By Deena Beasley Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by cholesterol drug Repatha and ...

Amgen just cleared its October 30 record with a $478.48 close, 2.68% above the prior peak and the fourth new high in barely a ...

Amgen appears safe, but the current valuation above $450/share may prove expensive by Q3 2026. Click here to read an analysis of AMGN stock now.

Biopharma industry veteran Jackie Elbonne, Ph.D., is retiring at the end of the year, leaving Amgen’s top quality spot to her ...

Amgen Inc.’s Q3 is near. Explore EPS growth, pipeline momentum, valuation, and dividend yield to see why it offers good ...

Oct 20 (Reuters) - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory ...